AZTR — Azitra Inc

Azitra Inc (AZTR) is a biotechnology company listed on AMEX. It is led by Francisco D. Salva, based in 21 Business Park Drive, Branford, CT, United States, 06405, with about 13 employees. Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Latest reported AZTR revenue for 2025-09-30 was $0. Net income was -$2.8M. AZTR currently screens at market cap $3.7M.

Use this AZTR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AZTR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AZTR SEC filings page. Lician reads the product cache first so this HTML stays unique to Azitra Inc even when a live quote feed is slow.